Supplier News: Piramal Pharma, Nanologica, Cellares & More
The latest from CDMOs, CMOs, and suppliers featuring Piramal Pharma Solutions, Nanologia/Ardena, Cellares/Stanford and Mabtech/Sai Life Sciences.
Chemicals/Chemical API Manufacturing
* Nanologica Acquires API Mfg Facility from Ardena
Formulation Development/Drug Product Manufacturing
* Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
* Cellares, Stanford in Gene-Edited Stem Cell Therapy Pact
General
* Mabtech, Sai Life Sciences in Immunology Assay Pact
Chemicals/Chemical API Manufacturing
Nanologica Acquires API Mfg Facility from Ardena
Nanologica, a Södertälje, Sweden-based CDMO, has completed the acquisition of all shares of Syntagon, a CDMO owned by Ardena, from Ardena Sweden. Syntagon’s facility specializes in active pharmaceutical ingredients (API) production and development, with the capacity to take APIs from early lead molecules to clinical studies and further into manufacturing.
The acquired company will be operated as an independent wholly owned subsidiary within the Nanologica Group. Ardena Södertälje AB will take back the name Syntagon AB, under which the company was founded and under which it is known in the industry. The current CEO of Ardena Södertälje AB, Annette Roos, will remain as CEO of Syntagon AB, and the business will continue to be conducted in the same premises and in a largely unchanged form.
The purchase price amounts to approximately SEK 8.6 million ($970,000) and will be paid in the form of newly issued shares in Nanologica. Syntagon is a CDMO with approximately 45 employees and in 2025 had sales of approximately SEK 80 million ($9 million).
Source: Nanologica
Formulation Development/Drug Product Manufacturing
Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
Piramal Pharma Solutions, a CDMO of active pharmaceutical ingredients and drug products, has announced the successful development, scale-up, and commercialization of a tablet-in-capsule drug-delivery system at its drug product facilities in Pithampur and Ahmedabad, India. Tablet-in-capsule technology offers developers a solution wherein different active ingredients are formulated into their own separate tablets or minitablets. The tablets are then placed together into a single capsule shell. This approach also allows incompatible active ingredients to be combined into one capsule.
Source: Piramal Pharma Solutions
Cellares, Stanford in Gene-Edited Stem Cell Therapy Pact
Cellares, a South San Francisco, California-based CDMO of cell therapies, has announced a collaboration with the Stanford Center for Definitive and Curative Medicine and the Stanford Innovative Medicines to automate manufacturing and release testing for gene-edited hematopoietic stem-cell therapies. Under the agreement, Cellares will establish a standardized platform manufacturing process and platform release assays, designed to apply across multiple indications. Automation efforts are already underway with the HARBOR KNOCK (safe harbor knock-in) gene-editing approach.
Source: Cellares
General
Mabtech, Sai Life Sciences in Immunology Assay Pact
Mabtech, a life-science tools company specializing in immunoassays, and Sai Life Sciences, a contract research organization and a CDMO of small-molecule active pharmaceutical ingredients (APIs) and intermediates, has announced a strategic collaboration that establishes Sai’s Boston laboratory as a co-marketed US execution and demonstration hub for the Mabtech EYRA platform. The EYRA platform incorporates software, automation readiness, and simultaneous detection of dozens of analytes in a single run with minimal hands-on time. Originally developed through a long-term R&D collaboration, EYRA enables streamlined and scalable immune-profiling workflows.
Under this collaboration, Mabtech and Sai will jointly deliver advanced immunology assay services, including high-sensitivity multiplex cytokine and phenotyping workflows, with the EYRA platform installed at Sai’s Boston discovery site.
Source: Sai Life Sciences
